CABA 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

CABA ▼ -4.18% at T+20d

NEUTRAL call ✗ call lost -4.18% · α vs SPY -9.82% · entry $3.83 → $3.67

Next anchor: T+60d in 7w

Currently $3.22 · -15.93% from $3.83 entry

Entry anchored
May 4, 2026
via day open

T+1d

+8.36%

call +8.36% · α +7.56%

$4.15

settled 5w ago

T+5d

-0.26%

call -0.26% · α -3.20%

$3.82

settled 4w ago

T+20d

-4.18%

call -4.18% · α -9.82%

$3.67

settled 8d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Cabaletta Bio announced it will present new clinical and translational data from 4 refractory patients treated with rese-cel without preconditioning in the RESET-PV trial at ASGCT 2026. The data showed biologic activity in 2 of 4 patients and a favorable safety profile, but the sample is small and early-stage. No financial impact or guidance changes were disclosed.

Actionable Insight

Monitor the ASGCT presentation on May 14 for full data. Early signs of activity without preconditioning could de-risk the program, but sample is too small to draw conclusions. Expect volatility around the event.

Key Facts

Data from 4 refractory pemphigus vulgaris patients receiving lowest-dose rese-cel without preconditioning will be presented at ASGCT on May 14, 2026.
2 of 4 patients demonstrated compelling clinical activity through 6 months; 3 of 4 remained off all immunomodulators and steroids.
Complete peripheral B cell elimination observed in 3 of 4 patients; one Grade 1 CRS, no ICANS.
Higher dose cohort in RESET-PV has been enrolled; durability data expected in H2 2026.
Initial dose cohort of RESET-SLE (lupus) is fully enrolled; initial data expected in H1 2026.

Financial Impact

No financial figures disclosed; pre-revenue biotech.

Risk Factors

Small sample size (n=4) limits statistical reliability.
Early-stage data may not replicate in larger cohorts.
No financial data or guidance provided; stock may move on sentiment alone.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

81% bullish (16 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-202389
Document: 0001193125-26-202389-index-headers.html	0001193125-26-202389
Document: 0001193125-26-202389-index.html	0001193125-26-202389
Document: 0001193125-26-202389.txt	0001193125-26-202389

12 reports for CABA

T+1T+5T+20T+60

71% Hit rate 5 of 7 directional calls best @ T+60▲ +12.73%Feb 28, 2026

Filters

Reports for CABA — sortable, filterable
	Type				Now
Jun 3, 2026 6d ago	8-K BULLISH ★ 7/10	$3.58 $3.51	▼ −1.96%	▼ −2.35%	$3.22 (−10.06%)
Jun 1, 2026 8d ago	DEFA14A NEUTRAL ★ 3/10	$3.67 $3.68	▲ +0.27%	▲ +0.13%	$3.22 (−12.26%)
May 14, 2026 26d ago	8-K BEARISH ★ 6/10	$3.61 $3.31	▲ +8.31%	▲ +7.08%	$3.22 (+10.80%)
May 14, 2026 26d ago	Press Release NEUTRAL ★ 4/10	$3.61 $3.31	▼ −8.31%	▼ −7.08%	$3.22 (−10.80%)
May 14, 2026 26d ago	8-K BULLISH ★ 7/10	$3.61 $3.31	▼ −8.31%	▼ −7.08%	$3.22 (−10.80%)
May 4, 2026 5w ago	8-K BEARISH ★ 7/10	$3.83 $4.15	▼ −8.36%	▼ −7.56%	$3.22 (+15.93%)
May 4, 2026 5w ago	424B5 BEARISH ★ 7/10	$3.83 $4.15	▼ −8.36%	▼ −7.56%	$3.22 (+15.93%)
May 4, 2026 5w ago	8-K NEUTRAL ★ 3/10	$3.83 $4.15	▲ +8.36%	▲ +7.56%	$3.22 (−15.93%)
Apr 28, 2026 6w ago	DEFA14A NEUTRAL ★ 2/10	$2.86 $2.78	▼ −2.80%	▼ −2.79%	$3.22 (+12.59%)
Apr 20, 2026 7w ago	8-K BULLISH ★ 7/10	$3.31 $3.13	▼ −5.29%	▼ −4.64%	$3.22 (−2.57%)

US Market Status

Market Closed — Opens Thu (11h 1m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access